Condition
Primary Mediastinal B-cell Lymphoma (PMBCL)
Total Trials
5
Recruiting
2
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Recruiting2
Not Yet Recruiting1
Active Not Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07463781Not Yet Recruiting
Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy
NCT04792489Phase 2Recruiting
DALY II USA/ MB-CART2019.1 for DLBCL
NCT06464861Phase 1RecruitingPrimary
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
NCT04049513Phase 1Active Not Recruiting
ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)
NCT02348216Phase 1Completed
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
Showing all 5 trials